Healthcare is entering a new era, and it is not being shaped by innovation alone. It is being shaped by confusion. Patients today are navigating a level of complexity that has never existed before. Specialty therapies are more advanced, treatment pathways are more nuanced, and the volume of information available online is overwhelming. While this […]
Read more
Pharma has invested billions into patient services over the past decade. Call centers, hub programs, nurse educators, and enrollment teams have all been built with the same goal in mind: help patients start and stay on therapy. On paper, the infrastructure is strong. In reality, it is quietly breaking down. The issue is not effort, […]
Read more
For more than a decade, pharmaceutical leaders have treated gross to net as a pricing problem. The focus has been on rebates, PBMs, formulary positioning, and increasingly complex contracting strategies. Entire teams are dedicated to modeling discount structures and negotiating access. Yet despite all of this effort, the gap between list price and net revenue […]
Read more
The pharmaceutical industry is facing a growing challenge that is quietly undermining both patient outcomes and commercial performance. While scientific innovation has accelerated and therapies have become more targeted and sophisticated, patient understanding has not kept pace. The result is what can only be described as a patient confusion crisis. For decades, pharmaceutical strategy has […]
Read more
Last week, the FDA released new draft guidance designed to streamline the development of biosimilar drugs by removing certain testing requirements. The goal is to accelerate competition and make biologic therapies more affordable. At first glance, this may appear to be a purely regulatory update. In reality, it highlights a much larger issue in healthcare. […]
Read more
Every year, millions of prescriptions are written that patients never start. Some patients never pick up their medication. Others start therapy but stop within weeks. For healthcare systems, pharmaceutical companies, and providers alike, this represents one of the most expensive and preventable failures in modern medicine. In the United States alone, roughly one in four […]
Read more
Today we released a press announcement that addresses something pharma leaders already feel in their forecasts, but rarely quantify directly: Patient dropout is quietly draining $250 billion from the U.S. pharmaceutical market every year. You can read the full announcement here:https://www.prnewswire.com/news-releases/pharma-is-losing-250-billion-to-patient-dropout-heres-how-to-stop-it-302696178.html Not because therapies do not work. Not because innovation has slowed. But because patients […]
Read more